Cargando…

Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study

Low bone mineral density (BMD) and osteoporosis remain frequent problems in patients with inflammatory bowel diseases (IBDs). Several guidelines with nonidentical recommendations exist and there is no general agreement regarding the optimal approach for osteoporosis screening in IBD patients. Clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Schüle, Solvey, Rossel, Jean-Benoît, Frey, Diana, Biedermann, Luc, Scharl, Michael, Zeitz, Jonas, Freitas-Queiroz, Natália, Kuntzen, Thomas, Greuter, Thomas, Vavricka, Stephan R., Rogler, Gerhard, Misselwitz, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459696/
https://www.ncbi.nlm.nih.gov/pubmed/28562531
http://dx.doi.org/10.1097/MD.0000000000006788
_version_ 1783242004624310272
author Schüle, Solvey
Rossel, Jean-Benoît
Frey, Diana
Biedermann, Luc
Scharl, Michael
Zeitz, Jonas
Freitas-Queiroz, Natália
Kuntzen, Thomas
Greuter, Thomas
Vavricka, Stephan R.
Rogler, Gerhard
Misselwitz, Benjamin
author_facet Schüle, Solvey
Rossel, Jean-Benoît
Frey, Diana
Biedermann, Luc
Scharl, Michael
Zeitz, Jonas
Freitas-Queiroz, Natália
Kuntzen, Thomas
Greuter, Thomas
Vavricka, Stephan R.
Rogler, Gerhard
Misselwitz, Benjamin
author_sort Schüle, Solvey
collection PubMed
description Low bone mineral density (BMD) and osteoporosis remain frequent problems in patients with inflammatory bowel diseases (IBDs). Several guidelines with nonidentical recommendations exist and there is no general agreement regarding the optimal approach for osteoporosis screening in IBD patients. Clinical practice of osteoporosis screening and treatment remains insufficiently investigated. In the year 2014, a chart review of 877 patients included in the Swiss IBD Cohort study was performed to assess details of osteoporosis diagnostics and treatment. BMD measurements, osteoporosis treatment, and IBD medication were recorded. Our chart review revealed 253 dual-energy x-ray absorptiometry (DXA) scans in 877 IBD patients; osteoporosis was prevalent in 20% of tested patients. We identified widely differing osteoporosis screening rates among centers (11%–62%). A multivariate logistic regression analysis identified predictive factors for screening including steroid usage, long disease duration, and perianal disease; even after correction for all risk factors, the study center remained a strong independent predictor (odds ratio 2.3–21 compared to the center with the lowest screening rate). Treatment rates for patients with osteoporosis were suboptimal (55% for calcium, 65% for vitamin D) at the time of chart review. Similarly, a significant fraction of patients with current steroid medication were not treated with vitamin D or calcium (treatment rates 53% for calcium, 58% for vitamin D). For only 29% of patients with osteoporosis bisphosphonate treatment was started. Treatment rates also differed among centers, generally following screening rates. In patients with longitudinal DXA scans, calcium and vitamin D usage was significantly associated with improvement of BMD over time. Our analysis identified inconsistent usage of osteoporosis screening and underuse of osteoporosis treatment in IBD patients. Increasing awareness of osteoporosis as a significant clinical problem in IBD patients might improve patient care.
format Online
Article
Text
id pubmed-5459696
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54596962017-06-12 Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study Schüle, Solvey Rossel, Jean-Benoît Frey, Diana Biedermann, Luc Scharl, Michael Zeitz, Jonas Freitas-Queiroz, Natália Kuntzen, Thomas Greuter, Thomas Vavricka, Stephan R. Rogler, Gerhard Misselwitz, Benjamin Medicine (Baltimore) 4500 Low bone mineral density (BMD) and osteoporosis remain frequent problems in patients with inflammatory bowel diseases (IBDs). Several guidelines with nonidentical recommendations exist and there is no general agreement regarding the optimal approach for osteoporosis screening in IBD patients. Clinical practice of osteoporosis screening and treatment remains insufficiently investigated. In the year 2014, a chart review of 877 patients included in the Swiss IBD Cohort study was performed to assess details of osteoporosis diagnostics and treatment. BMD measurements, osteoporosis treatment, and IBD medication were recorded. Our chart review revealed 253 dual-energy x-ray absorptiometry (DXA) scans in 877 IBD patients; osteoporosis was prevalent in 20% of tested patients. We identified widely differing osteoporosis screening rates among centers (11%–62%). A multivariate logistic regression analysis identified predictive factors for screening including steroid usage, long disease duration, and perianal disease; even after correction for all risk factors, the study center remained a strong independent predictor (odds ratio 2.3–21 compared to the center with the lowest screening rate). Treatment rates for patients with osteoporosis were suboptimal (55% for calcium, 65% for vitamin D) at the time of chart review. Similarly, a significant fraction of patients with current steroid medication were not treated with vitamin D or calcium (treatment rates 53% for calcium, 58% for vitamin D). For only 29% of patients with osteoporosis bisphosphonate treatment was started. Treatment rates also differed among centers, generally following screening rates. In patients with longitudinal DXA scans, calcium and vitamin D usage was significantly associated with improvement of BMD over time. Our analysis identified inconsistent usage of osteoporosis screening and underuse of osteoporosis treatment in IBD patients. Increasing awareness of osteoporosis as a significant clinical problem in IBD patients might improve patient care. Wolters Kluwer Health 2017-06-02 /pmc/articles/PMC5459696/ /pubmed/28562531 http://dx.doi.org/10.1097/MD.0000000000006788 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4500
Schüle, Solvey
Rossel, Jean-Benoît
Frey, Diana
Biedermann, Luc
Scharl, Michael
Zeitz, Jonas
Freitas-Queiroz, Natália
Kuntzen, Thomas
Greuter, Thomas
Vavricka, Stephan R.
Rogler, Gerhard
Misselwitz, Benjamin
Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
title Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
title_full Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
title_fullStr Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
title_full_unstemmed Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
title_short Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
title_sort widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the swiss ibd cohort study
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459696/
https://www.ncbi.nlm.nih.gov/pubmed/28562531
http://dx.doi.org/10.1097/MD.0000000000006788
work_keys_str_mv AT schulesolvey widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT rosseljeanbenoit widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT freydiana widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT biedermannluc widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT scharlmichael widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT zeitzjonas widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT freitasqueiroznatalia widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT kuntzenthomas widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT greuterthomas widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT vavrickastephanr widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT roglergerhard widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy
AT misselwitzbenjamin widelydifferingscreeningandtreatmentpracticeforosteoporosisinpatientswithinflammatoryboweldiseasesintheswissibdcohortstudy